Samsara BioCapital, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001744967

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 24 positions · Total reported value $1.22B · Top-10 concentration 90.5% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 42.3% · 4 new · 5 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +10.6% · vs SPY -4.2% · Prev Value $1.03B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Samsara BioCapital, LLC disclosed 24 equity positions with a combined reported value of $1.22B. The filing implies a focused portfolio: its ten largest positions account for 90.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were SRRK ($379.37M), ALMS ($178.55M), MLYS ($158.40M). By sector, the heaviest allocations are Health Care 94.5%, Industrials 5.5%. Versus the prior quarter, allocation shifted toward Industrials (+5.5pp) and away from Other (-0.7pp), Health Care (-4.8pp).

Versus the prior quarter, Samsara BioCapital, LLC opened 4 new positions, trimmed 5 and fully exited 2, a turnover rate of 42.3% of positions. The portfolio's overlap with the prior quarter was 77% of names.

The largest new positions opened in Q2 2026 were ALMR ($67.19M), PBLS ($15.22M), ARTV ($9.26M).

Of the 2 positions fully exited versus the prior quarter, the largest were ACLX ($6.99M), PVLA ($4.79M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ALMR ALAMAR BIOSCIENCES INC · $67.19M
  • PBLS PARABILIS MEDICINES INC · $15.22M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $9.26M
  • ELOX ELOXX PHARMACEUTICALS INC · $5.55M

Fully Exited (vs previous quarter)

  • ACLX ARCELLX INC · prev qtr: $6.99M
  • PVLA PALVELLA THERAPEUTICS INC · prev qtr: $4.79M

Insider Transactions (Form 4)

Latest Samsara BioCapital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Samsara BioCapital, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 24 positions worth $1.22B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • SEC registration: 801-113741 (status: Approved), registered 2018-07-27
  • Regulatory AUM (Form ADV): $2.17B as of 2026-06-26
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds
  • Website: samsaracap.com

Portfolio Structure

  • 24 positions · $1.22B reported value (Q2 2026)
  • Top 10 holdings = 90.5% of reported value
  • Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 31.2%
  • Average position size: $50.73M

Sector Tilt

  • Health Care 94.5%
  • Industrials 5.5%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 4 new, 2 added, 5 reduced, 2 exited
  • 13 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The Samsara BioCapital fund maintained a conservative stance in Q2 2026, with no significant changes in the top holdings' weights. This suggests a cautious approach to market volatility, possibly reflecting a preference for stability in the healthcare sector. 2. Key Moves: - Added: ALMR (Alamar Biosciences Inc.), a new holding in the Industrials sector, indicates a potential diversification into other sectors. - Reduced: KLRS (Kalaris Therapeutics Inc.), with a reduction of 0.5% from the previous quarter, suggests a slight shift away from this healthcare stock. - Added to: IVA (Inventiva SA ADS) with a significant increase of 21.6% in share count, indicating a strong belief in the company's potential. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be more passive, with a focus on holding rather than actively trading positions. - Sector Bias: The sector bias is heavily towards healthcare, with 8 out of the top 10 holdings in this sector. - Risk Appetite: The risk appetite is moderate, with a preference for stable companies and sectors, as evidenced by the low turnover and minimal changes in share counts. 4. Per-Holding One-Liner: - SRRK (Scholar Rock Hldg Corp): Develops treatments for serious diseases by modulating proteins. - ALMS (Alumis Inc): Develops novel biotherapeutics for the treatment of serious inflammatory diseases. - MLYS (Mineralys Therapeutics Inc): Focuses on the development of novel therapies for rare genetic diseases. - SEPN (Septerna Inc): Engaged in the discovery and development of novel therapies for orphan diseases. - ALMR (Alamar Biosciences Inc): Uses proprietary technology to develop novel therapeutics for cancer. - NGNE (Neurogene Inc COM): Specializes in the development of gene therapies for neurological disorders. - KLRS (Kalaris Therapeutics Inc): Develops therapies for cancer and other serious diseases. - SGP (Spyglass Pharma Inc): Focuses on the development of novel therapies for cancer and infectious diseases. - STRO (Sutro Biopharma Inc): Develops next-generation protein therapeutics for serious diseases. - IVA (Inventiva SA ADS): Develops treatments for metabolic diseases. 5. One-Sentence Style Summary: Samsara BioCapital maintained a stable healthcare-focused portfolio in Q2 2026, with a cautious approach to market volatility and a strategic diversification into the Industrials sector.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 94.5%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 6.90M $379.37M 31.16%
31.16%
Hold
2 6.35M $178.55M 14.67%
14.67%
Hold
3 5.87M $158.40M 13.01%
13.01%
Hold
4 3.15M $105.46M 8.66%
8.66%
Hold
5 2.48M $67.19M 5.52%
5.52%
New
6 1.72M $54.00M 4.44%
4.44%
Hold
7 12.88M $52.43M 4.31%
4.31%
Reduce
8 2.11M $46.97M 3.86%
3.86%
Hold
9 1.06M $35.29M 2.90%
2.90%
Hold
10 6.31M $23.87M 1.96%
1.96%
Add
11 736.24K $16.36M 1.34%
1.34%
Reduce
12 556.04K $15.22M 1.25%
1.25%
New
13 298.50K $11.24M 0.92%
0.92%
Hold
14 2.50M $10.40M 0.85%
0.85%
Hold
15 3.51M $9.93M 0.81%
0.81%
Hold
16 954.86K $9.26M 0.76%
0.76%
New
17 10.37M $7.88M 0.65%
0.65%
Add
18 600.00K $7.79M 0.64%
0.64%
Hold
19 55.09K $7.34M 0.60%
0.60%
Reduce
20 1.40M $6.52M 0.54%
0.54%
Reduce
21 400.00K $5.55M 0.46%
0.46%
New
22 3.43M $4.80M 0.39%
0.39%
Hold
23 353.72K $2.45M 0.20%
0.20%
Reduce
24 7.22M $1.19M 0.10%
0.10%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)

Historical Backtest (10 quarters)

Avg precision 84% · recall 84% · F1 84% · avg rank error 1.8 · Top-10 turnover 20%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% SRRK · RYZB · CRGX · MLYS · NGNE · ACLX · GRPH · SLRN · NKTX · SYRS SRRK · CRGX · MLYS · NGNE · NKTX · ACLX · LENZ · LYRA · SLRN · AVDL
2024-Q2 80% 80% 80% SRRK · CRGX · MLYS · NGNE · NKTX · ACLX · LENZ · LYRA · SLRN · AVDL CRGX · MLYS · SRRK · NGNE · ACLX · CLYM · NKTX · LENZ · AVDL · JSPR
2024-Q3 90% 90% 90% CRGX · MLYS · SRRK · NGNE · ACLX · CLYM · NKTX · LENZ · AVDL · JSPR CRGX · MLYS · SRRK · NGNE · ALMS · ACLX · LENZ · NKTX · CLYM · AVDL
2024-Q4 70% 70% 70% CRGX · MLYS · SRRK · NGNE · ALMS · ACLX · LENZ · NKTX · AVDL · CLYM SRRK · CRGX · SEPN · MLYS · NGNE · UPB · LENZ · ALMS · ACLX · ZYME
2025-Q1 80% 80% 80% SRRK · CRGX · SEPN · MLYS · NGNE · UPB · LENZ · ALMS · ACLX · ZYME SRRK · KLRS · MLYS · NGNE · ALMS · PVLA · SEPN · CRGX · LENZ · UPB
2025-Q2 100% 100% 100% SRRK · KLRS · MLYS · NGNE · ALMS · PVLA · SEPN · CRGX · LENZ · UPB SRRK · MLYS · SEPN · KLRS · NGNE · CRGX · UPB · ALMS · LENZ · PVLA
2025-Q3 90% 90% 90% SRRK · MLYS · SEPN · KLRS · NGNE · CRGX · ALMS · UPB · LENZ · GOSS MLYS · SRRK · KLRS · SEPN · NGNE · ALMS · UPB · GOSS · LENZ · AQST
2025-Q4 90% 90% 90% MLYS · SRRK · KLRS · SEPN · NGNE · ALMS · UPB · GOSS · LENZ · AQST SRRK · MLYS · KLRS · SEPN · ALMS · NGNE · IVA · GOSS · UPB · AQST
2026-Q1 80% 80% 80% SRRK · MLYS · KLRS · SEPN · ALMS · NGNE · IVA · GOSS · UPB · JBIO SRRK · MLYS · ALMS · SEPN · KLRS · SGP · NGNE · IVA · STRO · JBIO
2026-Q2 ★ 90% 90% 90% SRRK · MLYS · ALMS · KLRS · SEPN · SGP · NGNE · STRO · IVA · JBIO SRRK · ALMS · MLYS · SEPN · ALMR · NGNE · KLRS · SGP · STRO · IVA

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Samsara BioCapital, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Samsara BioCapital, LLC reported 24 equity positions worth $1.22B in aggregate; its largest disclosed positions were SRRK ($379.37M), ALMS ($178.55M), MLYS ($158.40M).

How large is Samsara BioCapital, LLC's portfolio?

Samsara BioCapital, LLC reported $1.22B of long equity holdings across 24 positions as of 2026-Q2. Top-10 holdings account for 90.5% of reported value.

What is Samsara BioCapital, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/samsara-biocapital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →